港股異動 | 微創醫療(0853.HK)續升7%再創新高 市值近1100億港元
格隆匯1月21日丨微創醫療(0853.HK)延續漲勢,現升至6.9%,高見59.2港元創歷史新高價,暫成交5.53億港元,總市值近1100億港元。近日,心通醫療通過了港交所聆訊,並於1月15日更新了聆訊後招股書;由摩根大通、花旗銀行及中金公司擔任聯席保薦人。廣發證券此前指出,公司引領中國多個高端器械細分領域的進口替代,堅持研發投入,產品不斷升級換代,未來以創新推動持續成長,國內業務的高成長和海外銷售規模的逐步擴大可期,維持微創醫療“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.